When the vitreous humour shrinks, the strong attachment results in a pulling force on the retina, which may lead to visual distortion, decreased visual acuity and central blindness.
JETREA ® breaks down the protein fibers which cause the abnormal traction between the vitreous and the macula that cause symptomatic VMA. By dissolving these proteins, JETREA ® releases the traction, and helps to complete the detachment of the vitreous from the macula.
It is estimated that around 500,000 patients in the US and five biggest markets in Europe alone suffer from this condition. 
There are no other pharmacological treatments available for symptomatic VMA. The current approach is 'watch and wait' until a patient becomes a candidate for surgical treatment, usually at a late stage of the disease.  , [ 3] A patient would then receive a surgical procedure and repair of the retina. However, for many patients this is not a suitable option, as irreversible damage to the retina may have already occurred.  , [ 5]References  ThromboGenics and Alcon internal estimates  Idiopathic macular hole. American Academy of Ophthalmology; 2008  Stalmans P. Management and intervention strategies for symptomatic vitreomacular adhesions. Retinal Physician 2011  Koerner F & Garweg J. Vitrectomy for macular pucker and vitreomacular traction syndrome. Doc Ophthalmol 1999;97:449-458  Dugel PU, Brown DM, Humayun MS et al. Symptomatic vitreomacular adhesion: diagnosis, pathologic implications, and management. Retina Today 2011;(Suppl):1-14 About JETREA ® (ocriplasmin) JETREA ® (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA ® is indicated for the treatment of symptomatic VMA. In Europe, JETREA ® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns. JETREA ® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion. JETREA ® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28. JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.